EMA Authorised: Tracleer (bosentan (as monohydrate)) — Janssen-Cilag International N.V.

View source ↗

Summary

The European Medicines Agency authorised Tracleer (bosentan) for systemic sclerosis and for pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Systemic Sclerosis

Drugs mentioned

• TRACLEER (bosentan)

Snippet

Status: Authorised. Therapeutic area: Scleroderma, Systemic;Hypertension, Pulmonary. MAH: Janssen-Cilag International N.V.. Decision date: 23/10/2024